Efficacy and safety of cathine (nor-pseudoephedrine) in the treatment of obesity: A randomized dose-finding study
Obesity Facts Sep 11, 2017
Hauner H, et al. - This study attempted to assess the utility and safety of increasing doses of cathine (nor-pseudoephedrine) as a weight-lowering agent in patients with obesity. It has been validated that cathine appears to be an effective weight-lowering agent for adjunct treatment of obesity, but additional clinical studies on its efficacy and safety are required. Methods
Go to Original
- For this study, overweight and obese patients (n = 241, mean BMI 34.6 ± 3.4 kg/m²) were assigned randomly to one of three doses of cathine (16 mg, 32 mg, 53.3 mg) or placebo in addition to a multimodal lifestyle intervention program in a multicenter, double-blind, controlled, dose-finding study for 24 weeks.
- Weight loss was considered as a primary endpoint.
- According to the data, treatment with the 3 doses of cathine resulted in a significantly greater weight loss compared to placebo over 24 weeks: 6.5 ± 4.2 kg for 16 mg cathine, 6.2 ± 4.7 kg for 32 mg cathine, and 9.1 ± 5.4 kg for 53.3 mg cathine versus 2.4 ± 4.4 kg for placebo (each p
- They noted that the percentage of patients losing > 5% / >10% of initial body weight was significantly greater for all doses of cathine than for placebo (each p They observed that heart rate increased dose-dependently (by 1.2 bpm under 16 mg, 5.8 bpm under 32 mg, and 6.2 bpm under 53.3 mg cathine), but no suspected unexpected serious adverse reactions were noted.
- It was showed that the overall dropout rate was 24.9%, with the highest rate in the placebo group (42.3%).
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries